A Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a dual PI3K delta/gamma inhibitor, in Patients with Relapsed or Refractory T-cell Lymphoma
The goal of this clinical research study is to find the highest tolerable dose of RP6530 that can be given to patients with periperal T-cell lymphoma (PTCL). Another goal of this study is to learn if the highest tolerable dose can help to control PTCL. The safety of this drug will also be studied.
Treatment Location: N/A
IRB Review and Approval Date: 09/24/2015
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: